16-68808692-G-C
Variant summary
Our verdict is Pathogenic. The variant received 14 ACMG points: 14P and 0B. PM5_SupportingPM2_SupportingPVS1_StrongPS4PS3
This summary comes from the ClinGen Evidence Repository: The c.532-1G>C variant is a canonical splice variant predicted to result in a truncated or absent protein (PVS1_Strong, PM5_Supporting). This variant is present once (1/245,906 alleles) in the gnomAD v2 cohort (PM2_Supporting; http://gnomad.broadinstitute.org). Additionally, this variant has been reported in six families meeting HDGC clinical criteria (PS4; internal laboratory data). RNA analysis demonstrated that this variant results in an out-of-frame transcript, r.532_547del p.(I178Tfs*32) (PS3; internal laboratory data). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_Strong, PM2_Supporting, PS4, PS3, PM5_Supporting. LINK:https://erepo.genome.network/evrepo/ui/classification/CA8129891/MONDO:0007648/007
Frequency
Consequence
NM_004360.5 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Publications
- blepharocheilodontic syndrome 1Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Ambry Genetics, Illumina, Labcorp Genetics (formerly Invitae), G2P
- CDH1-related diffuse gastric and lobular breast cancer syndromeInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, G2P
- hereditary breast carcinomaInheritance: AD Classification: DEFINITIVE Submitted by: Ambry Genetics
- hereditary diffuse gastric adenocarcinomaInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Ambry Genetics, Orphanet
- cleft soft palateInheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
- orofacial cleft 3Inheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
- blepharocheilodontic syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- familial ovarian cancerInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CDH1 | NM_004360.5 | c.532-1G>C | splice_acceptor_variant, intron_variant | Intron 4 of 15 | ENST00000261769.10 | NP_004351.1 | ||
CDH1 | NM_001317184.2 | c.532-1G>C | splice_acceptor_variant, intron_variant | Intron 4 of 14 | NP_001304113.1 | |||
CDH1 | NM_001317185.2 | c.-1084-1G>C | splice_acceptor_variant, intron_variant | Intron 4 of 15 | NP_001304114.1 | |||
CDH1 | NM_001317186.2 | c.-1288-1G>C | splice_acceptor_variant, intron_variant | Intron 4 of 14 | NP_001304115.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD2 exomes AF: 0.00000398 AC: 1AN: 250964 AF XY: 0.00000737 show subpopulations
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461816Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 727210 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:3
This variant causes a G to C nucleotide substitution at the -1 position of intron 4 of the CDH1 gene. Splice site prediction tools predict that this variant may have a significant impact on RNA splicing. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with esophagogastric cancer in the literature (PMID: 26556299). This variant has been identified in 1/250964 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of CDH1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Likely Pathogenic. -
The c.532-1G>C intronic variant results from a G to C substitution one nucleotide upstream from coding exon 5 of the CDH1 gene. This alteration was observed in 1 of 5054 African American women with breast cancer (Palmer JR et al. J Natl Cancer Inst, 2020 Dec;112:1213-1221). This alteration was also identified in an individual diagnosed with diffuse gastric cancer and colorectal cancer (Adib E et al. Br J Cancer, 2022 Mar;126:797-803). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and will result in the creation or strengthening of a novel splice acceptor site; however, direct evidence is insufficient at this time (Ambry internal data). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic. -
- -
not provided Pathogenic:2
- -
Canonical splice site variant expected to result in aberrant splicing, although in the absence of functional evidence the actual effect of this sequence change is unknown.; Not observed at significant frequency in large population cohorts (gnomAD); Observed in an individual with breast cancer (Palmer 2020); This variant is associated with the following publications: (PMID: 32427313) -
Hereditary diffuse gastric adenocarcinoma Pathogenic:2
This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. -
This sequence change affects an acceptor splice site in intron 4 of the CDH1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. This variant is present in population databases (rs771085839, gnomAD 0.007%). Disruption of this splice site has been observed in individuals with clinical features of hereditary diffuse gastric cancer syndrome (PMID: 26556299; Invitae). ClinVar contains an entry for this variant (Variation ID: 406644). Studies have shown that disruption of this splice site results in partial skipping of exon 5 and introduces a premature termination codon (Invitae). The resulting mRNA is expected to undergo nonsense-mediated decay. For these reasons, this variant has been classified as Pathogenic. -
CDH1-related diffuse gastric and lobular breast cancer syndrome Pathogenic:1
The c.532-1G>C variant is a canonical splice variant predicted to result in a truncated or absent protein (PVS1_Strong, PM5_Supporting). This variant is present once (1/245,906 alleles) in the gnomAD v2 cohort (PM2_Supporting; http://gnomad.broadinstitute.org). Additionally, this variant has been reported in six families meeting HDGC clinical criteria (PS4; internal laboratory data). RNA analysis demonstrated that this variant results in an out-of-frame transcript, r.532_547del p.(I178Tfs*32) (PS3; internal laboratory data). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_Strong, PM2_Supporting, PS4, PS3, PM5_Supporting. -
Familial cancer of breast Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at